Loading...

Anixa Biosciences

DB:CY71
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CY71
DB
$84M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Anixa Biosciences, Inc., a cancer-focused biotechnology company, develops both diagnostics and therapeutics to detect cancer. The last earnings update was 42 days ago. More info.


Add to Portfolio Compare Print
  • Anixa Biosciences has significant price volatility in the past 3 months.
CY71 Share Price and Events
7 Day Returns
2.2%
DB:CY71
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
21.9%
DB:CY71
-7.4%
DE Biotechs
-5.6%
DE Market
CY71 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Anixa Biosciences (CY71) 2.2% -6.8% -8.2% 21.9% - -
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • CY71 outperformed the Biotechs industry which returned -7.4% over the past year.
  • CY71 outperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
CY71
Industry
5yr Volatility vs Market

CY71 Value

 Is Anixa Biosciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Anixa Biosciences to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Anixa Biosciences.

DB:CY71 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:CY71
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.453 (1 + (1- 21%) (0%))
1.303
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.303 * 5.96%)
8%

Discounted Cash Flow Calculation for DB:CY71 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Anixa Biosciences is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:CY71 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8%)
2019 -8.23 Analyst x1 -7.62
2020 -9.76 Analyst x1 -8.36
2021 -3.77 Analyst x1 -2.99
2022 1.59 Analyst x1 1.17
2023 2.27 Est @ 42.55% 1.54
2024 2.94 Est @ 29.85% 1.85
2025 3.56 Est @ 20.97% 2.08
2026 4.08 Est @ 14.75% 2.21
2027 4.51 Est @ 10.39% 2.26
2028 4.84 Est @ 7.34% 2.24
Present value of next 10 years cash flows $-5.63
DB:CY71 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $4.84 × (1 + 0.23%) ÷ (8% – 0.23%)
$62.42
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $62.42 ÷ (1 + 8%)10
$28.92
DB:CY71 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $-5.63 + $28.92
$23.29
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $23.29 / 19.63
$1.19
DB:CY71 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:CY71 represents 0.88598x of NasdaqCM:ANIX
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.88598x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 1.19 x 0.88598
€1.05
Value per share (EUR) From above. €1.05
Current discount Discount to share price of €3.79
= -1 x (€3.79 - €1.05) / €1.05
-260.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Anixa Biosciences is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Anixa Biosciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Anixa Biosciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:CY71 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-01-31) in USD $-0.93
NasdaqCM:ANIX Share Price ** NasdaqCM (2019-04-24) in USD $4.28
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Anixa Biosciences.

DB:CY71 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:ANIX Share Price ÷ EPS (both in USD)

= 4.28 ÷ -0.93

-4.59x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Anixa Biosciences is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Anixa Biosciences is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Anixa Biosciences's expected growth come at a high price?
Raw Data
DB:CY71 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.59x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
12.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Anixa Biosciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Anixa Biosciences's assets?
Raw Data
DB:CY71 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-01-31) in USD $0.28
NasdaqCM:ANIX Share Price * NasdaqCM (2019-04-24) in USD $4.28
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:CY71 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:ANIX Share Price ÷ Book Value per Share (both in USD)

= 4.28 ÷ 0.28

15.21x

* Primary Listing of Anixa Biosciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Anixa Biosciences is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Anixa Biosciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Anixa Biosciences has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CY71 Future Performance

 How is Anixa Biosciences expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
12.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Anixa Biosciences expected to grow at an attractive rate?
  • Unable to compare Anixa Biosciences's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Anixa Biosciences's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Anixa Biosciences's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:CY71 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:CY71 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 12.7%
DB:CY71 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 76%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:CY71 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:CY71 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-10-31 24 -10 1
2021-10-31 13 -15 1
2020-10-31 3 -22 1
2019-10-31 0 -20 1
DB:CY71 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-01-31 1 -4 -17
2018-10-31 1 -4 -14
2018-07-31 1 -4 -10
2018-04-30 1 -4 -7
2018-01-31 0 -4 -5
2017-10-31 0 -4 -7
2017-07-31 1 -4 -6
2017-04-30 0 -3 -6
2017-01-31 0 -4 -7
2016-10-31 0 -3 -5
2016-07-31 0 -4 -5
2016-04-30 0 -3 -6

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Anixa Biosciences is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Anixa Biosciences's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:CY71 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Anixa Biosciences Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CY71 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-10-31 -0.36 -0.36 -0.36 1.00
2021-10-31 -0.60 -0.60 -0.60 1.00
2020-10-31 -0.94 -0.94 -0.94 1.00
2019-10-31 -0.95 -0.95 -0.95 1.00
DB:CY71 Past Financials Data
Date (Data in USD Millions) EPS *
2019-01-31 -0.93
2018-10-31 -0.79
2018-07-31 -0.62
2018-04-30 -0.43
2018-01-31 -0.37
2017-10-31 -0.58
2017-07-31 -0.60
2017-04-30 -0.62
2017-01-31 -0.80
2016-10-31 -0.57
2016-07-31 -0.60
2016-04-30 -0.66

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Anixa Biosciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Anixa Biosciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Anixa Biosciences has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CY71 Past Performance

  How has Anixa Biosciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Anixa Biosciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Anixa Biosciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Anixa Biosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Anixa Biosciences's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Anixa Biosciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Anixa Biosciences Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CY71 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-01-31 1.11 -17.04 7.99 8.28
2018-10-31 1.11 -14.00 6.91 6.81
2018-07-31 1.11 -10.48 5.95 4.73
2018-04-30 1.11 -6.80 4.75 2.15
2018-01-31 0.36 -5.26 4.54 1.92
2017-10-31 0.36 -7.02 4.41 1.60
2017-07-31 0.56 -6.28 3.61 1.66
2017-04-30 0.30 -5.59 2.74 1.59
2017-01-31 0.30 -7.02 2.70 1.55
2016-10-31 0.30 -5.02 2.71 1.56
2016-07-31 0.10 -5.26 2.63 1.85
2016-04-30 0.10 -5.76 3.42 1.56
2016-01-31 0.12 -6.72 4.61 1.17
2015-10-31 0.26 -1.38 5.51 0.71
2015-07-31 1.63 -3.24 6.65
2015-04-30 2.72 -1.23 6.33
2015-01-31 3.80 -2.24 6.32
2014-10-31 3.67 -9.61 6.41
2014-07-31 2.68 -9.38 6.68
2014-04-30 1.49 -12.37 7.78
2014-01-31 0.39 -11.60 7.78
2013-10-31 0.39 -10.08 7.99
2013-07-31 -0.01 -9.01 7.27 0.50
2013-04-30 0.24 -7.06 5.50 0.96
2013-01-31 0.49 -5.46 4.18 1.56
2012-10-31 0.94 -4.25 2.79 2.21
2012-07-31 1.40 -5.18 2.36 2.45
2012-04-30 1.60 -6.33 2.70 2.87

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Anixa Biosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Anixa Biosciences has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Anixa Biosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Anixa Biosciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Anixa Biosciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CY71 Health

 How is Anixa Biosciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Anixa Biosciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Anixa Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Anixa Biosciences has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Anixa Biosciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Anixa Biosciences has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Anixa Biosciences Company Filings, last reported 2 months ago.

DB:CY71 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-01-31 5.14 0.00 5.90
2018-10-31 5.18 0.00 5.06
2018-07-31 6.16 0.00 5.34
2018-04-30 6.02 0.00 5.42
2018-01-31 6.40 0.00 5.50
2017-10-31 7.92 0.00 6.84
2017-07-31 5.49 2.00 6.08
2017-04-30 3.59 3.00 5.13
2017-01-31 -3.82 3.00 2.00
2016-10-31 0.99 0.00 3.24
2016-07-31 1.72 0.00 3.95
2016-04-30 2.56 0.00 4.76
2016-01-31 3.59 0.00 6.13
2015-10-31 5.05 0.00 6.77
2015-07-31 6.00 0.00 7.56
2015-04-30 6.99 0.00 8.48
2015-01-31 8.26 0.00 10.46
2014-10-31 4.01 0.00 5.86
2014-07-31 0.15 6.76 6.20
2014-04-30 -4.85 6.63 2.67
2014-01-31 -5.67 7.18 3.23
2013-10-31 -3.32 5.55 0.90
2013-07-31 -3.24 5.45 0.98
2013-04-30 -1.45 5.45 1.27
2013-01-31 -1.32 5.41 1.71
2012-10-31 -1.19 5.03 0.84
2012-07-31 -0.89 5.00 1.05
2012-04-30 -0.34 5.00 1.68
  • Anixa Biosciences has no debt.
  • Anixa Biosciences currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Anixa Biosciences has sufficient cash runway for 1.4 years based on current free cash flow.
  • Anixa Biosciences has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 6.5% each year.
X
Financial health checks
We assess Anixa Biosciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Anixa Biosciences has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CY71 Dividends

 What is Anixa Biosciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Anixa Biosciences dividends.
If you bought €2,000 of Anixa Biosciences shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Anixa Biosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Anixa Biosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:CY71 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:CY71 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2022-10-31
2021-10-31
2020-10-31
2019-10-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Anixa Biosciences has not reported any payouts.
  • Unable to verify if Anixa Biosciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Anixa Biosciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Anixa Biosciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Anixa Biosciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Anixa Biosciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Anixa Biosciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CY71 Management

 What is the CEO of Anixa Biosciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Amit Kumar
COMPENSATION $11,592,634
AGE 54
TENURE AS CEO 1.8 years
CEO Bio

Dr. Amit Kumar is the President and Chief Executive Officer at Anixa Biosciences, Inc since July 6, 2017 and has been its Chairman of the Board and Director since August 23, 2016 and November 30, 2012 Respectively. From June 2015 to August 2016, Dr. Kumar served as Vice Chairman of the Board. Dr. Kumar served as a strategic advisor at Anixa Biosciences, Inc since September 2012. He has been Executive Chairman of the board of directors of Anixa Diagnostics Corporation since June 2015. He is Executive Chairman of Anixa. Dr. Kumar was Chief Executive Officer of Geo Fossil Fuels LLC since December 2010. From September 2001 to June 2010, he was President and Chief Executive Officer of CombiMatrix Corporation and also served as Director from September 2000 to June 2012. He was Vice President of Life Sciences of Acacia Research Corporation from July 2000 to August 2007 and also served as a Director from January 2003 to August 2007. Dr. Kumar has served as Chairman of the board of directors of Ascent Solar Technologies, Inc. since June 2007. He served as a Director of Aeolus Pharmaceuticals, Inc. from June 2004 to June 2018. Dr. Kumar is Chairman of BioCeryx, Inc., Actym Therapeutics and Ambrosia Medical, LLC. He has experience in technology driven startups, both at the board of directors and operating levels, in a broad variety of areas including finance, acquisitions, research and development and marketing, and as described above, has served as a director and/or officer of various publicly traded companies. Dr. Kumar has served on the board of the American Cancer Society since 2016. Dr. Kumar holds an A.B. in Chemistry from Occidental College. After graduate studies at Stanford University and Caltech, he received his Ph.D. from Caltech and completed his post-doctoral training at Harvard University.

CEO Compensation
  • Amit's compensation has increased whilst company is loss making.
  • Amit's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Anixa Biosciences management team in years:

2.4
Average Tenure
54
Average Age
  • The tenure for the Anixa Biosciences management team is about average.
Management Team

Amit Kumar

TITLE
Chairman
COMPENSATION
$12M
AGE
54
TENURE
1.8 yrs

Mike Catelani

TITLE
COO, CFO & Corporate Secretary
COMPENSATION
$2M
AGE
51
TENURE
2.4 yrs

John Roop

TITLE
Senior Vice President of Engineering
COMPENSATION
$275K
AGE
68
TENURE
6.6 yrs
Board of Directors Tenure

Average tenure and age of the Anixa Biosciences board of directors in years:

0.6
Average Tenure
67
Average Age
  • The average tenure for the Anixa Biosciences board of directors is less than 3 years, this suggests a new board.
Board of Directors

Amit Kumar

TITLE
Chairman
COMPENSATION
$12M
AGE
54
TENURE
2.7 yrs

Arnold Baskies

TITLE
Member of Scientific Advisory Board & Director
COMPENSATION
$202K
AGE
69

John Monahan

TITLE
Director
COMPENSATION
$202K
AGE
72
TENURE
2.7 yrs

Lew Titterton

TITLE
Lead Independent Director
COMPENSATION
$899K
AGE
74
TENURE
0.8 yrs

H. Shepard

TITLE
Member of Scientific Advisory Board

Dmitry Gabrilovich

TITLE
Member of Scientific Advisory Board

David Cavalier

TITLE
Director
COMPENSATION
$202K
AGE
49
TENURE
0.6 yrs

Jose Conejo-Garcia

TITLE
Member of Scientific Advisory Board
TENURE
0.5 yrs

Marco Davila

TITLE
Member of Scientific Advisory Board
TENURE
0.5 yrs

Linda Kelley

TITLE
Member of Scientific Advisory Board
AGE
65
TENURE
0.5 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Anixa Biosciences insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
22. Apr 19 Buy Lewis Titterton Individual 22. Apr 19 22. Apr 19 50,000 €3.63 €181,637
26. Oct 18 Buy Lewis Titterton Individual 25. Oct 18 25. Oct 18 2,000 €3.56 €7,122
25. Oct 18 Buy Amit Kumar Individual 25. Oct 18 25. Oct 18 11,000 €3.43 €37,722
19. Sep 18 Buy Michael Catelani Individual 18. Sep 18 18. Sep 18 2,250 €3.81 €8,568
18. Sep 18 Buy Amit Kumar Individual 14. Sep 18 14. Sep 18 3,000 €3.50 €10,496
17. Sep 18 Buy Lewis Titterton Individual 14. Sep 18 14. Sep 18 5,000 €3.41 €17,064
14. Sep 18 Buy Amit Kumar Individual 13. Sep 18 13. Sep 18 3,000 €3.29 €9,865
13. Sep 18 Buy Amit Kumar Individual 13. Sep 18 13. Sep 18 4,112 €3.39 €13,944
12. Sep 18 Buy Amit Kumar Individual 12. Sep 18 12. Sep 18 4,480 €3.43 €15,358
X
Management checks
We assess Anixa Biosciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Anixa Biosciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CY71 News

Simply Wall St News

CY71 Company Info

Description

Anixa Biosciences, Inc., a cancer-focused biotechnology company, develops both diagnostics and therapeutics to detect cancer. The company is developing the Cchek platform, a series of non-invasive blood tests for the early detection of solid tumors, which is based on the body’s immune response to the presence of a malignancy. It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs, which genetically engineer a patient’s own immune cells to fight cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.

Details
Name: Anixa Biosciences, Inc.
CY71
Exchange: DB
Founded: 1982
$75,061,498
19,628,129
Website: http://www.anixa.com
Address: Anixa Biosciences, Inc.
3150 Almaden Expressway,
Suite 250,
San Jose,
California, 95118,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM ANIX Common Stock Nasdaq Capital Market US USD 07. Oct 1983
DB CY71 Common Stock Deutsche Boerse AG DE EUR 07. Oct 1983
Number of employees
Current staff
Staff numbers
8
Anixa Biosciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 23:37
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/03/21
Last earnings filing: 2019/03/13
Last earnings reported: 2019/01/31
Last annual earnings reported: 2018/10/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.